Literature DB >> 19005731

Update in new medications for primary care.

Gerald W Smetana1, Jane S Sillman.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 19005731      PMCID： PMC2607517          DOI： 10.1007/s11606-008-0823-6

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  36 in total

1.  American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation.

Authors:  Linda Nici; Claudio Donner; Emiel Wouters; Richard Zuwallack; Nicolino Ambrosino; Jean Bourbeau; Mauro Carone; Bartolome Celli; Marielle Engelen; Bonnie Fahy; Chris Garvey; Roger Goldstein; Rik Gosselink; Suzanne Lareau; Neil MacIntyre; Francois Maltais; Mike Morgan; Denis O'Donnell; Christian Prefault; Jane Reardon; Carolyn Rochester; Annemie Schols; Sally Singh; Thierry Troosters
Journal:  Am J Respir Crit Care Med       Date:  2006-06-15       Impact factor: 21.405

2.  Chronic obstructive pulmonary disease: current burden and future projections.

Authors:  A D Lopez; K Shibuya; C Rao; C D Mathers; A L Hansell; L S Held; V Schmid; S Buist
Journal:  Eur Respir J       Date:  2006-02       Impact factor: 16.671

3.  Effects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertension.

Authors:  Ramón C Hermida; Diana E Ayala; Carlos Calvo; José E López; Artemio Mojón; María J Fontao; Rita Soler; José R Fernández
Journal:  Hypertension       Date:  2005-08-08       Impact factor: 10.190

4.  Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.

Authors:  Alberto Villamil; Steven G Chrysant; David Calhoun; Bonnie Schober; Huang Hsu; Linda Matrisciano-Dimichino; Jack Zhang
Journal:  J Hypertens       Date:  2007-01       Impact factor: 4.844

5.  Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

Authors:  Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves
Journal:  JAMA       Date:  2006-07-05       Impact factor: 56.272

6.  Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

Authors:  David Gonzales; Stephen I Rennard; Mitchell Nides; Cheryl Oncken; Salomon Azoulay; Clare B Billing; Eric J Watsky; Jason Gong; Kathryn E Williams; Karen R Reeves
Journal:  JAMA       Date:  2006-07-05       Impact factor: 56.272

7.  Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial.

Authors:  Serena Tonstad; Philip Tønnesen; Peter Hajek; Kathryn E Williams; Clare B Billing; Karen R Reeves
Journal:  JAMA       Date:  2006-07-05       Impact factor: 56.272

8.  Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

Authors:  Pablo Aschner; Mark S Kipnes; Jared K Lunceford; Matilde Sanchez; Carolyn Mickel; Debora E Williams-Herman
Journal:  Diabetes Care       Date:  2006-12       Impact factor: 19.112

9.  Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

Authors:  Bernard Charbonnel; Avraham Karasik; Ji Liu; Mei Wu; Gary Meininger
Journal:  Diabetes Care       Date:  2006-12       Impact factor: 19.112

Review 10.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

Authors:  Daniel J Drucker; Michael A Nauck
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.